166 related articles for article (PubMed ID: 29243843)
1. Signaling cascades in thyroid cancer: Increasing the armory of archers to hit bullseye.
Rashid FA; Mansoor Q; Tabassum S; Aziz H; Arfat WO; Naoum GE; Ismail M; Farooqi AA
J Cell Biochem; 2018 May; 119(5):3798-3808. PubMed ID: 29243843
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
3. Novel targeted therapies and immunotherapy for advanced thyroid cancers.
Naoum GE; Morkos M; Kim B; Arafat W
Mol Cancer; 2018 Feb; 17(1):51. PubMed ID: 29455653
[TBL] [Abstract][Full Text] [Related]
4. EGCG Mediated Targeting of Deregulated Signaling Pathways and Non-Coding RNAs in Different Cancers: Focus on JAK/STAT, Wnt/β-Catenin, TGF/SMAD, NOTCH, SHH/GLI, and TRAIL Mediated Signaling Pathways.
Farooqi AA; Pinheiro M; Granja A; Farabegoli F; Reis S; Attar R; Sabitaliyevich UY; Xu B; Ahmad A
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32290543
[TBL] [Abstract][Full Text] [Related]
5. Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice.
Tirrò E; Martorana F; Romano C; Vitale SR; Motta G; Di Gregorio S; Massimino M; Pennisi MS; Stella S; Puma A; Gianì F; Russo M; Manzella L; Vigneri P
Genes (Basel); 2019 Sep; 10(9):. PubMed ID: 31540307
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
[TBL] [Abstract][Full Text] [Related]
7. Targeted Therapy in Thyroid Cancer: State of the Art.
Valerio L; Pieruzzi L; Giani C; Agate L; Bottici V; Lorusso L; Cappagli V; Puleo L; Matrone A; Viola D; Romei C; Ciampi R; Molinaro E; Elisei R
Clin Oncol (R Coll Radiol); 2017 May; 29(5):316-324. PubMed ID: 28318881
[TBL] [Abstract][Full Text] [Related]
8. Evolving molecularly targeted therapies for advanced-stage thyroid cancers.
Bible KC; Ryder M
Nat Rev Clin Oncol; 2016 Jul; 13(7):403-16. PubMed ID: 26925962
[TBL] [Abstract][Full Text] [Related]
9. Drosophila as a novel therapeutic discovery tool for thyroid cancer.
Das T; Cagan R
Thyroid; 2010 Jul; 20(7):689-95. PubMed ID: 20578898
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
11. Luteolin mediated targeting of protein network and microRNAs in different cancers: Focus on JAK-STAT, NOTCH, mTOR and TRAIL-mediated signaling pathways.
Farooqi AA; Butt G; El-Zahaby SA; Attar R; Sabitaliyevich UY; Jovic JJ; Tang KF; Naureen H; Xu B
Pharmacol Res; 2020 Oct; 160():105188. PubMed ID: 32919041
[TBL] [Abstract][Full Text] [Related]
12. Editorial.
Farooqi AA; Ismail M
Cell Mol Biol (Noisy-le-grand); 2015 Oct; 61(6):1. PubMed ID: 26520390
[TBL] [Abstract][Full Text] [Related]
13. Overview of the oncogenic signaling pathways in colorectal cancer: Mechanistic insights.
Farooqi AA; de la Roche M; Djamgoz MBA; Siddik ZH
Semin Cancer Biol; 2019 Oct; 58():65-79. PubMed ID: 30633978
[TBL] [Abstract][Full Text] [Related]
14. Shikonin inhibits thyroid cancer cell growth and invasiveness through targeting major signaling pathways.
Yang Q; Ji M; Guan H; Shi B; Hou P
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1909-17. PubMed ID: 24106286
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.
Yeung KT; Cohen EE
Clin Cancer Res; 2015 Dec; 21(24):5420-6. PubMed ID: 26487760
[TBL] [Abstract][Full Text] [Related]
16. Cucurbitacin mediated regulation of deregulated oncogenic signaling cascades and non-coding RNAs in different cancers: Spotlight on JAK/STAT, Wnt/β-catenin, mTOR, TRAIL-mediated pathways.
Lin X; Farooqi AA
Semin Cancer Biol; 2021 Aug; 73():302-309. PubMed ID: 33152487
[TBL] [Abstract][Full Text] [Related]
17. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
Dadu R; Hu MN; Grubbs EG; Gagel RF
Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392
[TBL] [Abstract][Full Text] [Related]
18. Realizing the Potential of Blueberry as Natural Inhibitor of Metastasis and Powerful Apoptosis Inducer: Tapping the Treasure Trove for Effective Regulation of Cell Signaling Pathways.
Fayyaz S; Attar R; Xu B; Sabitaliyevich UY; Adylova A; Fares M; Qureshi MZ; Yaylim I; Alaaeddine N
Anticancer Agents Med Chem; 2020; 20(15):1780-1786. PubMed ID: 32160854
[TBL] [Abstract][Full Text] [Related]
19. New drugs for medullary thyroid cancer: new promises?
Spitzweg C; Morris JC; Bible KC
Endocr Relat Cancer; 2016 Jun; 23(6):R287-97. PubMed ID: 27185870
[TBL] [Abstract][Full Text] [Related]
20. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
Ruan M; Liu M; Dong Q; Chen L
J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
